Navigation Links
Boehringer Ingelheim Unveils Diabetes Pipeline
Date:6/6/2009

he management of this prevalent disease," said Dr. Thor Voigt, senior vice president, Medicine and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Type 2 diabetes is a progressive chronic condition that frequently requires long-term treatment. A range of treatment options and combination regimens are needed so physicians can tailor therapy to the individual patient needs. We are now awaiting results from additional ongoing studies which will further assess the full potential of linagliptin for the treatment of type 2 diabetes."

DPP-4 inhibitors are a newer class of oral hypoglycemics that target the incretin hormones GLP-1 and GIP, which are believed to be involved with regulating blood sugar.(2)

Linagliptin is a compound discovered by Boehringer Ingelheim and is being developed as an oral once-daily tablet for the treatment of type 2 diabetes. The compound is currently being studied in five pivotal Phase III clinical trials including more than 4,000 patients. These trials are fully recruited and underway globally and in many states across the U.S.(3)

Boehringer Ingelheim is also investigating sodium-dependent glucose co-transporter-2 inhibitors (SGLT-2 inhibitors), which are a new, emerging class of antidiabetic compounds that block tubular reabsorption of glucose in the kidney.(4) Phase IIb clinical trials for this innovative approach to diabetes treatment are underway. There are currently no SGLT-2 inhibitors approved by the U.S. Food and Drug Administration (FDA).

About the linagliptin (BI 1356) Phase II study

The aim of the 12-week, international, randomized, double-blind placebo-controlled study was to assess the efficacy and safety profile of linagliptin as add-on therapy in patients with type 2 diabetes who were failing to achieve glycemic control despite being treated with metformin.(1) The primary endpoint was the change in HbA1c from bas
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
5. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
8. Oregon Tourism Commission Unveils New Online Customer Service Training Program
9. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Seven leading cancer physicians ... Oncology Research participated in studies ... 2009 San Antonio Breast Cancer ... the Henry B. Gonzalez Convention ... . Fifteen others presented their ...
(Date:12/14/2009)... BEACH, Fla., Dec. 14 Perry Baromedical, ... years, announces the launch of the Sigma Elite, ... technology of the Sigma Elite is available on ... ) and has a Patent Pending. ,, The ... Data Capture Via Computerized System for Each ...
(Date:12/14/2009)... Diagnostics, Inc. is pleased to announce that the ... patent number 7,599,057 titled "Method and Apparatus for ... the company. The patent covers the core technology ... issuance of this patent supports the underlying strategy ... and commercialization," said Dave Dingott, CEO and President ...
Breaking Medicine Technology:US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Chinese Devil Dung Plant Could Be a Swine Flu Fighter 56608 1Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 1Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 2Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 3Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 1Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 2Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 3Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 4Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 5
(Date:12/15/2009)... -- Connectyx Technologies Holding Group Inc. (Pink Sheets: ... a higher listing level on the Pink Sheets ... positions Connectyx as a Transparent Company with Adequate ... President Ronn Schuman stated, "We are excited to ... to become a fully reporting company. This ...
(Date:12/15/2009)... clean transition to new coding system. , ... ... -- The American Academy of Professional Coders ( AAPC ) ... for health plans across the country beginning January. Developed specifically ... and reimbursement experts, the on-site trainings are designed to enable ...
(Date:12/15/2009)... your trust as the most caring, conscientious practice you have ever ... the Dermatology Center of Dallas, we can help to achieve this ... ... (PRWEB) December 15, 2009 -- The Dermatology Center of Dallas, a ... arrival of Jeri Beth “J.B.” Foshee, MD in their practice. ...
(Date:12/15/2009)... Marketstrat is pleased to announce the release of a new ... addresses world markets for clinical devices used to treat and ... ... CA (PRWEB) December 15, 2009 -- Marketstrat is pleased to ... Markets Worldwide.” The report specifically addresses world markets for ...
(Date:12/14/2009)... Young Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, and ... -- Nearly all unmarried young adults ages 18-29 believe ... men and 86% of women) and say that it ... now (86% of men and 88% of women), according ... Prevent Teen and Unplanned Pregnancy. Even so: ,, ...
Breaking Medicine News(10 mins):Health News:Connectyx Attains 'Current Listing' Status on Pink Sheets Exchange 2Health News:Connectyx Attains 'Current Listing' Status on Pink Sheets Exchange 3Health News:AAPC Now Offers On-site ICD-10 Training for Health Plans Nationwide 2Health News:AAPC Now Offers On-site ICD-10 Training for Health Plans Nationwide 3Health News:Jeri Beth “J.B.” Foshee, MD Joins Dermatology Center of Dallas 2Health News:Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail 2Health News:Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail 3Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3
... mumps beginning in Nova Scotia and now spreading in Ontario. ... affected. ,The latest outbreak of five people in ... has put health officials in top alert. ,Public-health ... booster shot, as the latest attacks prove that those vaccinated ...
... own wife or sons keep surfacing with monotonous regularity, especially from ... a South Carolina man held his wife and two sons captive ... since been sent to jail. ,The man identified as ... only that room was found tidy when the police raided ...
... more likely than men to develop osteoporosis, or porous bone, ... which can lead to debilitating - or even life-threatening - ... causes of osteoporosis are numerous, but in women, low estrogen ... ,As for men - new research at Washington University ...
... and the consequent quarantine of a woman has cost the ... cough up $75,000 dollars now. ,Based on ... case manager who had worked with high-risk obstetrics patients, isolated ... of February, said Deputy County Attorney Lori Alesio and Ryan's ...
... been unaffected by the rapidly increasing price of gas, which ... some parts of the United States . And consumers arent ... University professor has found. ,Research conducted by Wayne ... documents that Americans work attitudes have been affected as the ...
... ,"We call them dates," she said of the men with whom she ... dark hair off her slight shoulders and out of her smoky eyes. ... her large hands and Adam's apple seem obvious. But at first -- ... wasn't a girl her entire life. ,She prostitutes herself "about ...
Other Medicine News:Health News:Mumps Breaks Out In Canada 2Health News:Man Keeps Wife and Sons in Maggot-infested House 2Health News:Estrogen is Important for Bone Health in Men as Well as Women 2Health News:US County to Compensate Woman Wrongly Quarantined for TB 2Health News:Higher Gas Prices Leave Many Workers Running on Empty 2Health News:Making Change: The Cost of Being Transgender 2Health News:Making Change: The Cost of Being Transgender 3Health News:Making Change: The Cost of Being Transgender 4Health News:Making Change: The Cost of Being Transgender 5
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein G - .25 OD per sq. cm....
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Onyx Liquid Embolic System is a device utilized for the pre-surgical embolization of arteriovenous malformations (AVMs)....
Medicine Products: